Israel Englander Cellectis S.A. Transaction History

Millennium Management LLC

$213 Billion
Q3 2025

A detailed history of Israel Englander (Millennium Management LLC) transactions in Cellectis S.A. stock. As of the latest transaction made, Millennium Management LLC holds 57,740 shares of CLLS stock, worth $227,495. This represents 0.0% of its overall portfolio holdings.

Number of Shares

57,740

Previous 35,660 61.92%

Holding current value

$227,495

Previous $54,000 200.0%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$1.54 - $3.67 $34,003 - $81,033	22,080 Added 61.92%	57,740 $162,000
Q2 2025 Aug 14, 2025	SELL	$1.15 - $1.65 $78,423 - $112,520	-68,194 Reduced 65.66%	35,660 $54,000
Q1 2025 May 15, 2025	SELL	$1.22 - $2.13 $525,450 - $917,384	-430,697 Reduced 80.57%	103,854 $128,000
Q4 2024 Feb 14, 2025	BUY	$1.51 - $2.14 $807,172 - $1.14 Million	534,551 New	534,551 $962,000
Q2 2023 Aug 14, 2023	SELL	$1.72 - $2.12 $21,358 - $26,326	-12,418 Reduced 1.05%	1,167,641 $2.3 Million

Q1 2023 May 15, 2023	BUY	$1.83 - $3.84 $915,170 - $1.92 Million	500,093 Added 73.55%	1,180,059 $2.28 Million
Q4 2022 Feb 14, 2023	BUY	$1.85 - $2.6 $196,331 - $275,925	106,125 Added 18.49%	679,966 $1.43 Million
Q3 2022 Nov 14, 2022	BUY	$2.29 - $4.08 $276,861 - $493,272	120,900 Added 26.69%	573,841 $1.31 Million
Q2 2022 Aug 15, 2022	BUY	$2.39 - $4.93 $119,593 - $246,692	50,039 Added 12.42%	452,941 $1.28 Million
Q1 2022 May 16, 2022	BUY	$3.45 - $8.77 $962,505 - $2.45 Million	278,987 Added 225.14%	402,902 $1.83 Million
Q4 2021 Feb 14, 2022	SELL	$8.01 - $12.84 $498,422 - $798,969	-62,225 Reduced 33.43%	123,915 $1.01 Million
Q3 2021 Nov 15, 2021	BUY	$11.94 - $16.09 $1.43 Million - $1.93 Million	119,872 Added 180.89%	186,140 $2.35 Million
Q2 2021 Aug 16, 2021	BUY	$14.36 - $20.93 $513,815 - $748,896	35,781 Added 117.36%	66,268 $1.03 Million
Q1 2021 May 17, 2021	SELL	$18.19 - $33.25 $4.79 Million - $8.76 Million	-263,356 Reduced 89.62%	30,487 $616,000
Q3 2020 Nov 16, 2020	SELL	$15.7 - $20.84 $285,740 - $379,288	-18,200 Reduced 5.83%	293,843 $5.44 Million
Q2 2020 Aug 14, 2020	BUY	$8.21 - $21.02 $589,289 - $1.51 Million	71,777 Added 29.87%	312,043 $5.55 Million
Q1 2020 May 14, 2020	SELL	$7.81 - $18.82 $593,653 - $1.43 Million	-76,012 Reduced 24.03%	240,266 $2.21 Million
Q4 2019 Feb 14, 2020	SELL	$9.73 - $19.31 $77,236 - $153,282	-7,938 Reduced 2.45%	316,278 $5.42 Million
Q3 2019 Nov 14, 2019	BUY	$10.15 - $16.89 $1.48 Million - $2.46 Million	145,484 Added 81.4%	324,216 $3.37 Million
Q2 2019 Aug 15, 2019	SELL	$14.6 - $20.6 $8.94 Million - $12.6 Million	-612,368 Reduced 77.41%	178,732 $2.79 Million
Q2 2019 Aug 14, 2019	BUY	$14.6 - $20.6 $9.87 Million - $13.9 Million	676,111 Added 587.98%	791,100 $57.5 Million
Q1 2019 May 14, 2019	BUY	$15.53 - $19.75 $527,119 - $670,354	33,942 Added 41.88%	114,989 $2.11 Million
Q4 2018 Feb 14, 2019	SELL	$15.58 - $28.41 $581,196 - $1.06 Million	-37,304 Reduced 31.52%	81,047 $1.35 Million
Q3 2018 Nov 14, 2018	SELL	$25.99 - $30.6 $707,239 - $832,687	-27,212 Reduced 18.69%	118,351 $3.34 Million
Q2 2018 Aug 14, 2018	BUY	$27.78 - $38.53 $2.79 Million - $3.87 Million	100,515 Added 223.13%	145,563 $4.12 Million
Q1 2018 May 15, 2018	SELL	$27.78 - $35.19 $1.65 Million - $2.08 Million	-59,242 Reduced 56.81%	45,048 $1.42 Million
Q4 2017 Feb 14, 2018	BUY	$23.33 - $35.01 $2.27 Million - $3.4 Million	97,128 Added 1356.16%	104,290 $3.04 Million
Q3 2017 Nov 14, 2017	BUY	$21.65 - $32.18 $155,057 - $230,473	7,162	7,162 $204,000

Others Institutions Holding CLLS

# of Institutions

Shares Held

9.71M

Call Options Held

52.8K

Put Options Held

View Full List

About Cellectis S.A.

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $179M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

More about CLLS

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account